Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6828409 | Schizophrenia Research | 2009 | 6 Pages |
Abstract
Patients with schizophrenia/schizoaffective or bipolar disorders receiving ziprasidone 120-160Â mg/d experienced a statistically significant lower discontinuation rate compared with those receiving lower doses.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Leslie Citrome, Christopher Reist, Liisa Palmer, Leslie B. Montejano, Gregory Lenhart, Brian Cuffel, James Harnett, Kafi N. Sanders,